SCHEMBL2992363

SCHEMBL2992363

Cc1ccc(CNc2c(-c3ccccc3O)nc3cc(C)ccn23)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 6/20 0.72
MAPT P10636 6/20 0.72
KDM4E B2RXH2 3/20 0.57
ALDH1A1 P00352 3/20 0.57
SMN1; SMN2 Q16637 3/20 0.57
NPC1 O15118 2/20 0.57
RAB9A P51151 2/20 0.57
POLB P06746 1/20 0.57
NR1H4 Q96RI1 4/20 0.52
MEN1 O00255 1/20 0.52
MAPK1 P28482 1/20 0.52
GFER P55789 1/20 0.52
KMT2A Q03164 1/20 0.52
HPGD P15428 2/20 0.51
PKM P14618 2/20 0.49
PKLR P30613 1/20 0.49
SIRT1 Q96EB6 1/20 0.48
TP53 P04637 1/20 0.47
ATM Q13315 3/20 0.47
NPSR1 Q6W5P4 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2989961 0.94 GAA (0.67) GAAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2987674 0.92 GAA (0.62) GAAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2982183 0.92 GAA (0.62) GAAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2979685 0.91 GAA (0.60) GAAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2989981 0.90 GAA (0.64) GAAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2979602 0.86 GAA (0.60) GAAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2988829 0.86 GAA (0.60) GAAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2986401 0.86 MAPT (0.60) GAAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2989983 0.85 GAA (0.64) GAAMAPTKDM4EALDH1A1SMN1; SMN2
SCHEMBL2992236 0.84 GAA (0.63) GAAMAPTKDM4EALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100173930-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-07-08 US claimed
WO-2008016648-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 WO claimed
US-20100173930-A1 Certain Chemical Entities, Compositions and Methods CYTOKINETICS, INC. 2010-07-08 US disclosed
WO-2008016648-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100173930-A1 Certain Chemical Entities, Compositions and Methods TNNC1, TNNI3, TNNT2 GAA 820/4885MAPT 218/4885KDM4E 4444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.